APPLE STUDY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this trial are to assess the efficacy of a lipid-lowering agent (atorvastatin) on the development of atherosclerosis that predisposes children with SLE to cardiovascular events in adulthood, to assess the safety of intermediate-term (36 months) treatment of children with atorvastatin, to further characterize the course of SLE in children, by establishing a cohort of pediatric SLE patients to be followed prospectively, and to establish a mechanism for conducting clinical trials in rare pediatric rheumatic diseases using the Children's Arthritis and Rheumatology Research Alliance (CARRA) (formerly Pediatric Rheumatology Research Network (PRRN)) and the Duke Clinical Research Institute (DCRI).